Elicio Q2 net loss $8.2M; Phase 2 AMPLIFY-7P trial misses primary endpoint

Elicio Therapeutics, Inc.

Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS pancreatic cancer did not meet primary endpoint; evaluating R0 resected subgroup for Phase 3 strategy.
Q2 2026 net loss $8.2M ($0.43/share) vs $10.6M ($0.66/share) in Q2 2025; R&D expense $6.8M, G&A $3.6M.
Cash $23.5M at June 30, 2026; July 2026 $15.0M registered direct offering; runway into Q1 2027.
Plans Phase 1 combo study of ELI-002 7P + RAS inhibitor ± anti-PD-1 in metastatic pancreatic cancer, Q4 2026; multiple complete responses observed.
MSK-led Phase 1 neoadjuvant trial of ELI-002 7P + chemo + checkpoint inhibition activated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.